HLL Biotech Limited, a subsidiary of Central Public Sector miniratna company HLL Lifecare Limited has entered into a long-term supply and technology transfer agreement with the Institute of Immunology, Zagreb, Croatia for mass production of measles vaccine in India.
Addressing a press conference in Thiruvananthapuram, HLL Lifecare Limited Chairman Dr.M.Ayyappan said the company will produce 80 million doses of measles vaccine, for the Indian market, which will meet a major share of the Government requirements.
The partnership will lead to the development of the next generation of vaccines, he said. Construction work has begun on Hindustan Biotech’s Integrated Vaccine Complex at Chengalpet in Tamil Nadu at a cost of 594 crore rupees. He said the Vaccine Complex would become fully operative by the end of 2016.
Set up in 1893, the Institute of Immunology, Zagreb, is one of the worlds oldest manufacturers of immunobiological medicines. It is a vaccine manufacturing and research facility of the Croatian government and a premier provider for measles vaccine strains in most parts of the world.
Addressing a press conference in Thiruvananthapuram, HLL Lifecare Limited Chairman Dr.M.Ayyappan said the company will produce 80 million doses of measles vaccine, for the Indian market, which will meet a major share of the Government requirements.
The partnership will lead to the development of the next generation of vaccines, he said. Construction work has begun on Hindustan Biotech’s Integrated Vaccine Complex at Chengalpet in Tamil Nadu at a cost of 594 crore rupees. He said the Vaccine Complex would become fully operative by the end of 2016.
Set up in 1893, the Institute of Immunology, Zagreb, is one of the worlds oldest manufacturers of immunobiological medicines. It is a vaccine manufacturing and research facility of the Croatian government and a premier provider for measles vaccine strains in most parts of the world.
